NEW YORK (360Dx) – Newly minted publicly traded cell-based diagnostics firm Celcuity today reported a net loss of $1.8 million, or $.26 per share, for the third quarter of 2017, compared to a net loss of $868,520, or $.13 per share, for the third quarter of 2016.

On an adjusted basis, the firm's Q3 net loss broadened to $1.4 million, or $.20 per share, compared to a net loss of $795,245, or $.12 per share, for Q3 2016.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.